GeneOne Life Science researches and develops next-generation biologics and new small molecule drugs. We are developing DNA vaccines against emergent and chronic viral diseases such as COVID-19, SFTS, CCHF, Powassan, MERS, Zika, and hepatitis C. We are also studying DNA-based protein drugs and DNA-based monoclonal antibodies that improve upon existing biopharmaceuticals. We are also developing two small molecule drugs, one that stimulates natural innate immunity to fight against upper respiratory diseases including sinusitis and a second anti-inflammatory molecule that is being developed for the treatment of uveitis and acute ischemic kidney disease. Both of these drugs have also shown remarkable potential in the prevention and treatment of COVID-19 and are currently being tested in clinical trials. GeneOne Life Science has continuously invested in innovative technologies through cooperation with multinational pharmaceutical companies and domestic · overseas research institutes, and is constantly striving to develop new drugs. We promise to contribute to maximizing shareholder value and promoting human health by establishing itself as a global company leading the development of new next-generation biologics. Thank you.